Effect of an increased clopidogrel maintenance dose or lansoprazole co‐administration on the antiplatelet response to clopidogrel in CYP2C19‐genotyped healthy subjects
- 11 February 2010
- journal article
- letter
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 8 (3) , 610-613
- https://doi.org/10.1111/j.1538-7836.2009.03729.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trialsThe Lancet, 2009
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- Can We Override Clopidogrel Resistance?Circulation, 2009
- Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent ThrombosisThe American Journal of Cardiology, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With AspirinJournal of the American College of Cardiology, 2008
- Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patientsPharmacogenetics and Genomics, 2007
- Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjectsBlood, 2006